Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer

NCT02649855 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02649855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 19, 2016
Completion date
December 5, 2023
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, prostatic, prostate cancer, prostate neoplasms